ATAI logo

ATAI Life Sciences N.V. Common Shares


ATAI: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.


Show ATAI Financials

Consumer Interest
SEC Filings

Recent trades of ATAI by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by ATAI's directors and management

Government lobbying spending instances

  • $20,000 Jul 20, 2022 Issue: None
  • $30,000 Apr 20, 2022 Issue: Pharmacy
  • $50,000 Jan 20, 2022 Issue: Pharmacy
  • $50,000 Oct 20, 2021 Issue: None
  • $15,000 Aug 09, 2021 Issue: Pharmacy Health Issues
U.S. Patents

New patents grants

  • Patent Title: N,n-dimethyltryptamine compositions and methods Mar. 14, 2023
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of ATAI in WallStreetBets Daily Discussion


Recent insights relating to ATAI

CNBC Recommendations

Recent picks made for ATAI stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ATAI

Corporate Flights

Flights by private jets registered to ATAI